akst4290
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jan 16, 2020 (NCT04369430)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- EotaxinINHIBITOR
CCL11 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05038020 | Phase 2 | Aug 17, 2021 | Alkahest, Inc. |
| NCT04499235 | Phase 2 | Jan 30, 2020 | Alkahest, Inc. |
| NCT04331730 | Phase 2 | Jan 28, 2020 | Alkahest, Inc. |
| NCT04369430 | Phase 2 | Jan 16, 2020 | Alkahest, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alkahest, Inc. | For profit | 4 | 4 | 1 | 2020 |
1 organizations
Page 1 / 1